drugset / Trial / NCT00698828

SUN11031 in Cachexia Associated With Chronic Obstructive Pulmonary Disease (COPD)

NCT00698828 ↗

Phase 2 Completed 227 enrolled Daiichi Sankyo
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate SUN11031 for subcutaneous injection compared to placebo in subjects with cachexia associated with Chronic Obstructive Pulmonary Disease (COPD) to determine the effect on physical performance and body composition.

Timeline

Start
2008-05-15
Primary completion
2009-10-08
Completion
2009-10-08

Drugs

EvaluationDrugModalityDoseRoute
Subject SUN11031 Unknown 20 ug/kg Subcutaneous
Subject SUN11031 Unknown 40 ug/kg Subcutaneous